Entry into a Material Definitive Agreement · Results of Operations and Financial Condition
Item 1.01 Entry into Material Definitive Agreement As previously disclosed, on March 24, 2026, Cingulate Inc. (the “Company”) entered into an ATM Sales Agreement, or the ATM Agreement, with A.G.P./Alliance Global Partners (“A.G.P.”) as sales agent (the “Agent”), pursuant to which the Company may offer and sell, our common stock, par value $0.0001 per share, or common stock, having an aggregate off…
Filed Nov 13, 2026Accepted Nov 13, 2026, 5:19 PM ESTCIK 1862150Accession 0001493152-26-051841
We are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM (PTRTM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”) and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer (“EBL”) designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. We believe there remains a significant, unmet need within the current treatment paradigm for true once-daily ADHD stimulant medications with lasting duration and a superior side effect profile to better serve the needs of patients throughout their entire active-day.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into Material Definitive Agreement
As previously disclosed, on March 24, 2026,
Cingulate Inc. (the “Company”) entered into an ATM Sales Agreement, or the ATM Agreement, with A.G.P./Alliance Global Partners
(“A.G.P.”) as sales agent (the “Agent”), pursuant to which the Company may offer and sell, our common stock,
par value $0.0001 per share, or common stock, having an aggregate offering price of up to $100,000,000, from time to time, through the
Agent.
On November 13, 2026, the Company entered
into Amendment No. 2 to the ATM Agreement (the “Amendment”) with A.G.P. and Maxim Group LLC (“Maxim”) solely
to add Maxim Group LLC as an Agent under the ATM Agreement. The foregoing description of the Amendment is qualified in its entirety by
reference to the full text of the Amendment, which is filed as Exhibit 10.1 hereto.
Item
2.02. Results of Operations and Financial Condition.
On
November 13, 2026, Cingulate Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026 and
providing a regulatory update. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference. The information
in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit Description
No.
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
10.1 Amendment No. 1 to ATM Agreement, by and among the Company, A.G.P. and Maxim, dated November 13, 2026
99.1 Press Release dated November 13, 2026
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm
Exhibit
99.1
Cingulate
Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
Manufacturing
Work Addressing FDA CMC Information Requests Substantially Completed
NDA
Resubmission Expected Between December 2026 and January 2027
KANSAS
CITY, Kan., Nov. 13, 2026 - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed
Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results
for the quarter ended September 30, 2026, and announced that it has substantially completed the manufacturing work required to address
the U.S. Food and Drug Administration’s (FDA) chemistry, manufacturing and controls (CMC) information requests for CTx-1301. The
Company expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027.
“With
the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301,
and we expect to do so by January 2027, potentially sooner,” stated Cingulate Chairman and CEO Shane J. Schaffer. “Importantly,
the FDA’…